Researchers have delivered the first doses of experimental HIV vaccine antigens developed using Moderna’s mRNA technology.
According to a recent press release, Moderna and the International AIDS Vaccine Initiative (IAVI) have officially begun a Phase 1 clinical trial of their experimental HIV vaccine antigens. The vaccine, designed using Moderna’s mRNA technology, stimulates the production of broadly neutralizing antibodies called bnABs. These special proteins can then attach to the HIV spikes; thus, preventing the virus from attacking other cells.
Last year, IAVI and Scripps Research announced results of a Phase 1 trial for an experimental HIV vaccine. The trial, IAVI G001, assessed the vaccine candidate’s safety and ability to stimulate the production of bnABs. Results revealed that 97% of the participants developed the B-cell response required for production of bnABs. Next, the researchers partnered with Moderna to create an mRNA-based version of their vaccine. Thus, allowing a faster production of their design.
The current Phase1 trial, IAVI G002 will build on the results from the earlier proof-of-concept trial. It will not only assess the B-cell response to the vaccine antigens but also a booster version. A total of 56 healthy HIV-negative adult participants are part of the trial. As part of the study design, 48 participants will receive one or two doses of the vaccine antigens, 32 will receive it along with the booster vaccine, and the remaining eight will receive only the booster.
Next, the researchers will monitor these patients for an immune response and any adverse events. It is expected to last until 2023.